Description
Valprid CR 500 Tablet -10’s
Valprid CR 500 Tablet is a controlled-release (CR) formulation manufactured by Micro Labs Ltd, combining Sodium Valproate (333 mg) and Valproic Acid (145 mg), which together correspond to 500 mg of sodium valproate. This medication is primarily used as an anticonvulsant to manage various neurological and psychiatric conditions.
✅ Indications
Valprid CR 500 Tablet is prescribed for:
-
Epilepsy: To control and prevent seizures, including generalized tonic-clonic, absence, and myoclonic seizures.
-
Bipolar Disorder: To stabilize mood and prevent manic episodes.
-
Migraine Prophylaxis: To reduce the frequency and severity of migraine attacks.
The controlled-release formulation ensures a steady release of the active ingredients, maintaining therapeutic levels over an extended period.
⚠️ Side Effects
Common side effects may include:
-
Drowsiness or dizziness
-
Nausea or vomiting
-
Tremors
-
Weight gain
-
Hair loss
-
Menstrual irregularities
-
Loss of appetite
-
Sleep disturbances
Serious side effects are rare but may include liver dysfunction, pancreatitis, and blood disorders. Regular monitoring through blood tests is recommended during treatment.
⚠️ Precautions and Contraindications
-
Contraindications:
-
Hypersensitivity to valproate or any component of the formulation.
-
Severe liver disorders or a history of liver disease.
-
Urea cycle disorders.
-
Porphyria (a group of liver disorders).
-
-
Use with caution in:
-
Patients with renal impairment.
-
Individuals with a history of pancreatitis.
-
Pregnant or breastfeeding women (only if clearly necessary).
-
Regular monitoring of liver function and blood counts is advised during treatment.
📝 Dosage and Administration
-
Take the tablet as prescribed by your healthcare provider, typically once or twice daily.
-
Swallow the tablet whole with a glass of water; do not chew or crush.
-
It is advisable to take the medication with food to minimize gastrointestinal discomfort.
-
Do not discontinue the medication abruptly; consult your doctor before making any changes to your dosage regimen.
⚠️ Additional Information
-
Alcohol: Avoid consumption of alcohol during treatment, as it may increase the risk of adverse effects such as drowsiness and dizziness.
-
Driving: Be cautious when driving or operating machinery, as the medication may cause drowsiness or affect coordination.
-
Pregnancy: Valprid CR 500 Tablet is classified as a Category D drug for pregnancy, indicating a risk to the fetus. Use during pregnancy should be considered only if the potential benefit justifies the potential risk to the fetus.
Here’s a table of alternative brands to Valprid CR 500 (Sodium Valproate 500 mg, controlled-release) available in India:
Brand Name | Composition | Type | Manufacturer | Approx. Price (INR) | Pack Size |
---|---|---|---|---|---|
Valprol CR 500 | Sodium Valproate 333 mg + Valproic Acid 145 mg | Controlled-Release | Intas Pharmaceuticals | ₹132.52 | 10 tablets |
Valparin Chrono 500 | Sodium Valproate 333 mg + Valproic Acid 145 mg | Controlled-Release | Sanofi India Ltd | ₹122.40 | 15 tablets |
Valporate Chrono 500 | Sodium Valproate 333 mg + Valproic Acid 145 mg | Controlled-Release | Abbott | ₹83.30 | 10 tablets |
Divaa OD 500 | Divalproex Sodium (equivalent to 500 mg) | Once-Daily (OD) | Intas Pharmaceuticals | ₹112.00 | 10 tablets |
Divalid ER 500 | Divalproex Sodium Extended Release 500 mg | Extended Release | Cipla Ltd | ₹115.00 | 10 tablets |
Epival ER 500 | Divalproex Sodium Extended Release 500 mg | Extended Release | Abbott | ₹125.00 | 10 tablets |
Valance OD 500 | Divalproex Sodium 500 mg | Once-Daily (OD) | Sun Pharmaceutical Industries | ₹110.00 | 10 tablets |
🔍 Notes:
-
All these formulations are used for epilepsy, bipolar disorder, and migraine prophylaxis.
-
Divalproex sodium is a compound of valproic acid and sodium valproate in a stable form and is often better tolerated.
-
Controlled-release (CR), extended-release (ER), and once-daily (OD) forms provide steady therapeutic levels and reduce dosing frequency.
Reviews
There are no reviews yet.